29 completed, 19 unknown, 16 recruiting, 8 not yet recruiting. 12 Not applicable, 9 Phase 2, 9 Phase 4, 7 Phase 3, 1 Early Phase 1.
Follow Takayasu Arteritis: new trials by email Literature Review of Takayasu Arteritis trials Research Report on Takayasu Arteritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-Axial Field of View (LAFOV) [18F]FDG PET/CT Imaging in Large Vessel Vasculitis (LVV): Protocol Optimisation Study. [18F]FDG Long-Axial Field of View (LAFOV)-PET/CT, CT Angiogram, MR Angiogram - Large Vessel Vasculitis, Takayasu Arteritis | Not applicable | Not yet recruiting | Imperial College London | 18 | 2026-12-01 | 2026-10-16 |
| Inflammatory Disease Biobank for Immunophenotyping and Cardiovascular Research Pericarditis, Tako-TSUBO Cardiomyopathy | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 300 | 2026-09-01 | 2026-08-10 | |
| Monitoring Disease Activity in Patients With Takayasu Arteritis With the OMERACT Takayasu Ultrasound Score (OTUS) Takayasu Arteritis (TAK) | Not yet recruiting | IRCCS San Raffaele | 100 | 2026-07-01 | 2026-05-11 | |
| Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis Vanakizumab, Ivarmacitinib, Prednisone - Takayasu Arteritis (TAK) | Phase 4 | Not yet recruiting | Chinese SLE Treatment And Research Group | 180 | 2026-04-01 | 2026-03-05 |
| Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients Secukinumab, Standard of Care (SOC) - Takayasu Arteritis, Large Vessel Vasculitis | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 52 | 2026-04-01 | 2026-03-27 |
| Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases Dengue 1,2,3,4 (attenuated) vaccine - Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA) | Phase 4 | Recruiting | University of Sao Paulo General Hospital | 477 | 2026-03-16 | 2026-07-20 |
| Effect of Pirfenidone on TA Fibrosis Pirfenidone Capsules, Placebo - Takayasu Arteritis | Phase 4 | Not yet recruiting | Shanghai Zhongshan Hospital | 92 | 2025-12-20 | 2026-01-08 |
| EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases observational study - Myocarditis, ANCA Associated Vasculitis | Recruiting | Assistance Publique - Hôpitaux de Paris | 5000 | 2025-11-19 | 2026-06-05 | |
| Investigating Management, Perspectives and Attitudes Towards Care in Takayasu Arteritis Questionnaire - Takayasu Arteritis, Takayasu Arteritis (TAK) | Recruiting | University of Edinburgh | 50 | 2025-10-01 | 2026-01-20 | |
| Physical and Psychosocial Parameters in Takayasu Arteritis and Behçet's Disease: A Comparative Study With Healthy Controls No intervention (observational study) - Takayasu Arteritis, Behçet's Disease | Recruiting | ÖZLEM NUR TOK YAMAN | 30 | 2025-09-11 | 2025-12-10 | |
| Global Initiative on Takayasu Arteritis (GITA) Takayasu Arteritis (TAK), Takayasu's Arteritis | Recruiting | Marmara University | 1000 | 2025-08-05 | 2026-04-30 | |
| The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis Deucravacitinib, Adalimumab - Takayasu Arteritis (TAK) | Phase 4 | Not yet recruiting | Chinese SLE Treatment And Research Group | 50 | 2025-06-15 | 2025-06-10 |
| Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission Tociliuzumab, Infliximab, Adalimumab - Takayasu Arteritis | Not applicable | Recruiting | Marmara University | 40 | 2025-06-15 | 2026-03-25 |
| Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV) Bosentan and dapagliflozin - Large Vessel Vasculitis, Giant Cell Arteritis (GCA) | Phase 2 | Recruiting | University of Edinburgh | 60 | 2025-03-21 | 2026-01-14 |
| Turkish Adaptation of the VascuQoL-6 Quality of Life Scale Takayasu Arteritis, Behcet Disease | Completed | Uşak University | 37 | 2025-03-01 | 2025-08-22 | |
| A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases. Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA) | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 10000 | 2025-01-30 | 2025-01-09 | |
| Evaluation of Platelet Aggregability in Patients with Takayasu's Arteritis Clopidogrel - Takayasu Arteritis (TAK), Vasculitis, Systemic | Active not recruiting | Jose Carlos Nicolau | 100 | 2024-10-14 | 2025-02-04 | |
| A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis Prednisone, Methotrexate, Tocilizumab - Takayasu Arteritis | Phase 4 | Recruiting | Shanghai Zhongshan Hospital | 124 | 2024-06-28 | 2024-10-17 |
| Upadacitinib for Refractory Takayasu Arteritis Takayasu Arteritis | Completed | Liu Tian | 12 | 2024-03-19 | 2026-03-30 | |
| ICF in Takayasu Arteritis ICF - Takayasu Arteritis | Not applicable | Completed | Pamukkale University | 15 | 2024-02-21 | 2024-05-14 |
Showing 20 of 76. Sign in to see all of them.
Giant Cell Arteritis (22) · Granulomatosis with Polyangiitis (15) · Polyarteritis Nodosa (15) · Microscopic Polyangiitis (13) · Behcet Syndrome (12) · Churg-Strauss Syndrome (12) · Vasculitis (11) · IgA Vasculitis (9) · Systemic Vasculitis (9) · Arthritis, Rheumatoid (8) · Vasculitis, Central Nervous System (7) · Arthritis, Juvenile (6) · Lupus Erythematosus, Systemic (5) · Scleroderma, Systemic (5)
Aortic Arch Syndromes (76) · Aortic Diseases (76) · Skin Diseases (76) · Skin and Connective Tissue Diseases (76) · Skin Diseases, Vascular (75) · Vascular Diseases (75) · Arteritis (73) · Cardiovascular Diseases (73) · Vasculitis (65) · Nervous System Diseases (29) · Autoimmune Diseases (28) · Immune System Diseases (28) · Brain Diseases (26) · Central Nervous System Diseases (26) · Cerebrovascular Disorders (26)
tocilizumab (7) · Adalimumab (5) · Infliximab (5) · Prednisone (5) · tofacitinib (5) · Methotrexate (3) · Cyclophosphamide (2) · Glucocorticoids (2) · Leflunomide (2) · Observation (2) · Prednisolone (2) · Abatacept (1) · Angioplasty (1) · Antilymphocyte Serum (1) · Bosentan (1)
Shanghai Zhongshan Hospital (7) · Assistance Publique - Hôpitaux de Paris (6) · University of Pennsylvania (6) · Chinese SLE Treatment And Research Group (5) · University of South Florida (5) · Peking Union Medical College Hospital (3) · Instituto Nacional de Cardiologia Ignacio Chavez (2) · Liu Tian (2) · Marmara University (2) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (2) · University of Edinburgh (2) · University of Sao Paulo (2) · University of Sao Paulo General Hospital (2) · AbbVie (1) · Aimin Dang (1)
China (23) · United States (20) · Canada (8) · Turkey (Türkiye) (8) · United Kingdom (7) · Brazil (6) · France (6) · Japan (3) · Mexico (3) · South Korea (3) · Argentina (2) · Denmark (2) · Germany (2) · India (2) · Italy (2)
Peter A. Merkel, MD, MPH (6) · Lindi Jiang, PhD (4) · Peter A Merkel, MD, MPH (4) · Amanda M. Terry, MA (3) · Xinping Tian, MD (3) · Megan Clowse, MD, MPH (2) · Peter C. Grayson, MD (2) · Peter Merkel, MD, MPH (2) · Alexis Guedon (1) · Andreas Diamantopoulos, MD (1) · Antoine Sreih, MD (1) · Arne Slungaard (1) · Bruno BG Gualano, Professor (1)
PMID 10068416, PMID 16221103, PMID 17332971, PMID 20054700, PMID 20055902, PMID 24574239, PMID 24675165, PMID 26304483, PMID 26712071, PMID 27924855, PMID 27940595, PMID 28133925, PMID 28133931, PMID 28629556, PMID 28780030, PMID 29086462, PMID 29798770, PMID 30229280, PMID 30670069, PMID 31278892, PMID 31649025, PMID 31775708, PMID 31785185, PMID 32702156, PMID 32943098, PMID 33544969, PMID 34394103, PMID 34843469, PMID 35612893, PMID 36895331, PMID 37540159, PMID 38488572, PMID 38825350, PMID 38825354, PMID 40104212, PMID 40411764, PMID 40804749, PMID 42025686, PMID 42111310, PMID 42399917
U54AR057319 (4), 268200700036C-5-0-1 (1)